VIDEO: Recent developments in glomerular diseases

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

There's been a lot of progress in the last few years across virtually all of the glomerular diseases. Couple areas that I've been particularly excited about are the recent study called Advocate, which was a study of Avacopan a C5A inhibitor in ANCA Vasculitis with renal involvement. And basically this seems to be an agent that we can use as an opportunity to reduce the exposure to prednisone and steroids. And that's a recurring theme, I think, in all of the discussions regarding these diseases is to get more targeted therapy rather than more sort of general therapy with prednisone.

Another area that's of potential interest is some progress in IgA Nephropathy. So one of the controversies in this condition is sort of you have to treat with agents for a long time to impact a slowly progressive disease in general. And so there have been some interesting controversies about steroids, but one thing that's particularly exciting is some more targeted therapies. So there's a targeted release formulation of budesonide which looks encouraging in IgA as well as a number of other newer treatments that are potentially coming down the pike as far as options for this condition. But I think the general progress seems to be sort of molecular-based treatments rather than sort of generalized medications that lower the immune system. So we're really getting into a precision medicine era of more targeted treatments.